| 伊马替尼治疗胃肠道间质瘤的继发性耐药机制 |
| |
| 引用本文： | 刘传,王宁.伊马替尼治疗胃肠道间质瘤的继发性耐药机制[J].国际肿瘤学杂志,2010,37(12). |
| |
| 作者姓名： | 刘传 王宁 |
| |
| 作者单位： | 第二军医大学附属长海医院肿瘤科,上海,200433 |
| |
| 摘 要： | 甲磺酸伊马替尼是一种高效的酪氨酸激酶抑制剂,在临床上用于进展期或手术不能切除胃肠道间质瘤(GIST)的患者.虽然取得了很好的疗效,但是容易产生耐药,耐药机制主要有原发性耐药和继发性耐药,其中继发性耐药成为近些年研究的焦点.通过对继发性耐药机制的研究,可探讨新的治疗策略.
|
| 关 键 词： | 胃肠道间质瘤 抗药性 肿瘤 |
Mechanisms of secondary resistance to imatinib in gastrointestinal stromal tumors |
| |
| LIU Chuan,WANG Ning.Mechanisms of secondary resistance to imatinib in gastrointestinal stromal tumors[J].Journal of International Oncology,2010,37(12). |
| |
| Authors: | LIU Chuan WANG Ning |
| |
| Abstract: | Imatinib is an effective tyrosine kinase inhibitor, used in the treatment of advanced or inoperable gastrointestinal stromal tumors. Despite its efficacy, resistance is often developed among a portion of patients. Resistance to imatinib can be divided into primary and secondary resistance, with the latter becoming the focus of many recent researches. Research on the mechanisms of secondary resistance may lead to the identification of novel therapeutic strategies. |
| |
| Keywords: | Gastrointestinal stromal tumours Drug resistance neoplasm |
| 本文献已被 万方数据 等数据库收录！ |
|
